Bevacizumab effective in severe ROP

Article

Bevacizumab can produce remarkable results in infants with severe retinopathy of prematurity (ROP), according to a free paper presented at the All India Ophthalmological Society meeting held in Bangalore earlier this year.

Bevacizumab can produce remarkable results in infants with severe retinopathy of prematurity (ROP), according to a free paper presented at the All India Ophthalmological Society meeting held in Bangalore earlier this year.

Dr Alay S. Banker, a surgeon practising in Ahmedabad, India, presented results from 14 eyes of nine infants with severe ROP who received one injection of 0.75 mg of bevacizumab. The infants had a mean birth weight of 1133 g and a mean gestation period of 29.2 weeks; they were treated at a mean age of 2.3 months. Follow-up ranged from three to 12 months. Eight eyes had previously received laser treatment and six eyes received bevacizumab as a first-line treatment.

All eyes fully recovered, with rubeosis disappearing within two days of treatment, and no eyes requiring repeated treatments or experiencing complications.

Dr Banker therefore concluded that bevacizumab can produce remarkable results in infants with severe ROP. He also noted that the agent presents a good option for first-line treatment of ROP, particularly in India where laser or cryotherapy treatment is not widely available.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.